Patent application number | Description | Published |
20100004306 | PIGF-1 Assay and kits and components thereof - The present disclosure relates to, among other things, methods for determining whether a subject receiving treatment with a drug has obtained an efficacious blood level of the drug. Moreover, the present disclosure also relates to methods of determining whether a subject predisposed to or suffering from a disease will benefit from treatment with a drug, and the response of a subject receiving treatment (e.g., such as for cancer) by monitoring biomarkers of angiogenesis. In particular, the disclosure relates to PlGF-1 companion diagnostic methods and products. | 01-07-2010 |
20100015637 | PIGF-1 ASSAY AND KITS AND COMPONENTS THEREOF - The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits. | 01-21-2010 |
20100266575 | SOLUBLE FMS-LIKE TYROSINE KINASE-1 (sFLT-1) ANTIBODY AND RELATED COMPOSITION, KIT, METHODS OF USING, AND MATERIALS AND METHOD FOR MAKING - An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid. | 10-21-2010 |
20130040407 | SOLUBLE FMS-LIKE TYROSINE KINASE-1 (sFLT-1) ANTIBODY AND RELATED COMPOSITION, KIT, METHODS OF USING, AND MATERIALS AND METHOD FOR MAKING - An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid. | 02-14-2013 |
Patent application number | Description | Published |
20120214209 | Methods For Producing End-Products From Carbon Substrates - The present invention provides means for the production of desired end-products of in vitro and/or in vivo bioconversion of biomass-based feed stock substrates, including but not limited to such materials as starch and cellulose. In particularly preferred embodiments, the methods of the present invention do not require gelatinization and/or liquefaction of the substrate. | 08-23-2012 |
20120276587 | RECOMBINANT MICROORGANISMS FOR ENHANCED PRODUCTION OF MEVALONATE, ISOPRENE, AND ISOPRENOIDS - The invention features compositions and methods for the increased production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids in microorganisms by engineering a microorganism for increased carbon flux towards mevalonate production in the following enzymatic pathways: (a) citrate synthase, (b) phosphotransacetylase, (c) acetate kinase, (d) lactate dehydrogenase, (e) malic enzyme, and (f) pyruvate dehydrogenase such that one of more of the enzyme activity is modulated. In addition, production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids can be further enhanced by the heterologous expression of the mvaE and mvaS genes (such as, but not limited to, mvaE and mvaS genes from the organisms | 11-01-2012 |
20120276603 | PRODUCTION OF MEVALONATE, ISOPRENE, AND ISOPRENOIDS USING GENES ENCODING POLYPEPTIDES HAVING THIOLASE, HMG-COA SYNTHASE AND HMG-COA REDUCTASE ENZYMATIC ACTIVITIES - The invention features compositions and methods for the increased production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids in microorganisms via the heterologous expression of the mvaE and mvaS genes from the organisms | 11-01-2012 |
20130164809 | PRODUCTION OF ISOPRENE UNDER REDUCED OXYGEN INLET LEVELS - This invention relates to methods for producing isoprene by culturing recombinant cells (e.g., cells engineered to produce isoprene) under reduced oxygen inlet levels. | 06-27-2013 |
20150037861 | PRODUCTION OF MEVALONATE, ISOPRENE, AND ISOPRENOIDS USING GENES ENCODING POLYPEPTIDES HAVING THIOLASE, HMG-COA SYNTHASE AND HMG-COA REDUCTASE ENZYMATIC ACTIVITIES - The invention features compositions and methods for the increased production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids in microorganisms via the heterologous expression of the mvaE and mvaS genes from the organisms | 02-05-2015 |
Patent application number | Description | Published |
20090047923 | Method and System for Using Cellular/Wireless Phones and Devices for Retrieving Emergency Related Personal Data - The present invention discloses a method, system and a program storage device for remotely accessing medically relevant data stored on a server and provides remote access over a cellular or PCS communications network employing either a SMS or MMS communication protocol allowing dissemination of an individual's medically relevant data in an emergency, wherein the server authenticates each accessing PCS device by determining whether said accessing PCS device ID is stored in an emergency medical profile database and sending the user inputted emergency related personal data if the accessing PCS device ID is found in the emergency medical database device. | 02-19-2009 |
20110296245 | SYSTEM AND METHOD FOR A STAGGERED EXECUTION ENVIRONMENT - A staggered execution environment is provided to safely execute an application program against software failures. In an embodiment, the staggered execution environment includes one or more probe virtual machines that execute various portions of an application program and an execution virtual machine that executes the same application program within a time delay behind the probe virtual machines. A virtualization supervisor coordinates the execution of the application program on one or more probe virtual machines. The probe virtual machines are used to detect and correct software failures prior to the execution virtual machine encountering them. The virtualization supervisor embargos output data in order to ensure that erroneous data is not released which may adversely affect external processes. | 12-01-2011 |
20120084464 | Obfuscating Network Traffic from Previously Collected Network Traffic - An obfuscated network traffic server is operative to generate obfuscated network traffic. The obfuscated network traffic server maintains the relationship between extracted application content and extracted network header content such that the obfuscated network traffic is indistinguishable from the monitored network traffic. The obfuscated network traffic server may include a network monitor operative to monitor network traffic and to extract application content and network header content from the monitored network traffic. The obfuscated network traffic server may also include a data masking processor operative to mask a portion of the separated application content and/or the separated network header content. The obfuscated network traffic server may further include a masking attribute selector operative to specify the attributes of the application content and/or the network header content that is to be masked. | 04-05-2012 |
20120226947 | SYSTEM AND METHOD FOR A STAGGERED EXECUTION ENVIRONMENT - A staggered execution environment is provided to safely execute an application program against software failures. In an embodiment, the staggered execution environment includes one or more probe virtual machines that execute various portions of an application program and an execution virtual machine that executes the same application program within a time delay behind the probe virtual machines. A virtualization supervisor coordinates the execution of the application program on one or more probe virtual machines. The probe virtual machines are used to detect and correct software failures prior to the execution virtual machine encountering them. The virtualization supervisor embargos output data in order to ensure that erroneous data is not released which may adversely affect external processes. | 09-06-2012 |
Patent application number | Description | Published |
20090012071 | 4-SUBSTITUTED-1H-ISOTHIAZOLO[5,4-B][1,4]OXAZINO[2,3,4-IJ]QUINOLINE-7,8(2H,9H)-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS - The present invention provides compounds of the formula that possess antimicrobial activity. Certain compounds provided herein possess potent antibacterial, antiprotozoal, or antifungal activity. Particular compounds provided herein are also potent and/or selective inhibitors of microbial DNA synthesis and reproduction. The invention provides anti-microbial compositions, including pharmaceutical compositions, containing a compound of the invention and one or more or more carriers. The invention provides pharmaceutical compositions containing a 4-substituted- | 01-08-2009 |
20110223132 | ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS - The invention provides compounds and salts of Formula I and Formula | 09-15-2011 |
20120040959 | 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS - The invention provides compound and salts of Formula I and II, disclosed herein, which includes compounds of Formula A and Formula B: | 02-16-2012 |